Past, present and development possibility of cardiooncology
Keywords:
кардиотоксичность
факторы риска
антрациклины
трастузумаб
ингибиторы иммунных контрольных точек
кардиопротекция
cardiotoxity
risk factors
anthracycline
trastuzumab
immune checkpoint inhibitors
cardioprotection
Abstract
The material is devoted to a new interdisciplinary direction “Cardioncology”. Patients with oncological diseases have an increased risk of developing cardiovascular complications associated with antitumor therapy. The article describes the historical stages of the use of antitumor treatment leading to the development of cardiotoxicity, presents the current state of the problem and considers the prospects for further development. The data of russian and foreign studies in this area are presented.



